Zobrazeno 1 - 10
of 295
pro vyhledávání: ''
Autor:
Gandhi Damaj, Steven Le Gouill, Christophe Bonnet, Hervé Ghesquières, David Sibon, Marc André, Emmanuel Itti, Loïc Chartier, Françoise Kraeber-Bodéré, Luc Fornecker, Hervé Tilly, Vincent Ribrag, Franck Morschhauser, Jean-Philippe Jais, Caroline Bodet-Milin, Alina Berriolo-Riedinger, Krimo Bouhabdallah, Philippe Ruminy, Guillaume Cartron, Catherine Thieblemont, Remy Gressin, Reda Bouhabdallah, Corinne Haioun, Lucie Oberic, Thierry Jo Molina, René-Olivier Casasnovas, Pierre Feugier, Josette Brière, Thierry Lamy, Hervé Maisonneuve
Publikováno v:
Blood. 137:2307-2320
Rituximab plus polychemotherapy is the standard of care in diffuse large B-cell lymphoma (DLBCL). GAINED, a randomized phase 3 trial, compared obinutuzumab to rituximab. Transplant-eligible patients (18-60 years) with an untreated age-adjusted Intern
Autor:
Martin Kaiser, Anna Hockaday, David A Cairns, J. Anthony Child, Walter M Gregory, John R Jones, Mark T. Drayson, Charlotte Bradbury, Zoe Craig, Graham Jackson, Gareth J. Morgan, Andrea Paterson, Matthew W Jenner, Gordon Cook, Faith E. Davies, Charlotte Pawlyn, Roger G. Owen
Publikováno v:
Blood. 136:1091-1104
Newly diagnosed multiple myeloma (NDMM) patients treated with immunomodulatory drugs are at high risk of venous thromboembolism (VTE), but data are lacking from large prospective cohorts. We present thrombosis outcome data from Myeloma IX (n = 1936)
Autor:
Bianca Rocca, Francesca Palandri, Giovanna Petrucci, Chiara Paoli, Cristina Bucelli, Benedetta Porro, Nicola Vianelli, Francesco Rodeghiero, Elena Rossi, Alessandra Iurlo, Carlo Patrono, Irene Bertozzi, Alessandro M. Vannucchi, Maria Luigia Randi, Andrea Timillero, Monica Carpenedo, Mauro Di Ianni, Giuseppe Carli, Alfredo Dragani, Silvia Betti, Denise Soldati, Elena Maria Elli, Eloise Beggiato, Valerio De Stefano, Daniele Cattaneo, Giuseppe Lanzarone, Alberto Tosetto, Viviana Cavalca, Marco Ruggeri, Giorgina Specchia, Alessandra Ricco, Paola Ranalli
Publikováno v:
Blood. 136:171-182
Essential thrombocythemia (ET) is characterized by abnormal megakaryopoiesis and enhanced thrombotic risk. Once-daily low-dose aspirin is the recommended antithrombotic regimen, but accelerated platelet generation may reduce the duration of platelet
Autor:
Christopher J. Forlenza, Brigitte Senechal, Nancy A. Kernan, Susan E. Prockop, Yasmin Khakoo, David A. Williams, Isabelle Riviere, Peter G. Steinherz, Craig S. Sauter, Jaap Jan Boelens, Michel Sadelain, Lewis B. Silverman, Farid Boulad, Glenn Heller, Richard J. O'Reilly, Victoria Szenes, Jae H. Park, Barbara Spitzer, Neerav Shukla, Andrew L. Kung, Rachel Kobos, Steven P. Margossian, Renier J. Brentjens, Xiuyan Wang, Maria Cancio, Kevin J Curran
Publikováno v:
Blood. 134:2361-2368
Chimeric antigen receptor (CAR) T cells have demonstrated clinical benefit in patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). We undertook a multicenter clinical trial to determine toxicity, feasibility, and respo
Autor:
Darren Foard, Sajitha Sachchithanantham, Cristina Quarta, Shameem Mahmood, Faye Sharpley, Philip N. Hawkins, Oliver C Cohen, Richa Manwani, Helen J. Lachmann, Carol J. Whelan, Marianna Fontana, Julian D. Gillmore, Ashutosh D. Wechalekar
Publikováno v:
Blood. 134:2271-2280
Bortezomib is a standard therapy in light-chain amyloidosis (AL), but little is known about response duration. A difference in involved amyloidogenic and uninvolved serum-free light chains (dFLC)10 mg/L (low dFLC response) predicts survival in AL pat
Autor:
Joseph P. McGuirk, Ran Reshef, Michael R. Grunwald, Mary Eapen, Natasha Kekre, Rizwan Romee, Ephraim J. Fuchs, Christopher G. Kanakry, Mahasweta Gooptu, Robert J. Soiffer, Claudio G. Brunstein, Nilanjan Ghosh, Mark A. Schroeder, Saurabh Chhabra, Yoshihiro Inamoto, Ian McNiece, Filippo Milano, Dipenkumar Modi, Rohtesh S. Mehta, Monzr M. Al Malki, Joseph H. Antin, Edmund K. Waller, Marco Mielcarek, Andrew St. Martin, Christopher Bredeson, Scott R. Solomon, Mukta Arora
Publikováno v:
Blood
Post transplant cyclophosphamide (PTCy) graft-versus-host disease (GVHD) prophylaxis has allowed haploidentical (Haplo) transplantation to be performed with results similar to that after matched unrelated donor (MUD) transplantation with traditional
Autor:
Andreas Tiede, Heiner Wedemeyer, Sonja Werwitzke, Frank Gf Donnerstag, Arnold Ganser, Ulrich J. Sachs, Andreas Czwalinna, Günter U. Höglinger, Benjamin Maasoumy, Joachim K. Krauss, Karin Weißenborn, Rolf Bikker
Publikováno v:
Blood
We report 5 cases of prothrombotic immune thrombocytopenia after exposure to the ChAdOx1 vaccine (AZD1222, Vaxzevria) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Patients presented 5 to 11 days after first vaccination. The s
Autor:
Simona Berardi Vilei, Andreas Lohri, Mario Bargetzi, Ulrich Mey, Micaela Hernberg, Stefan Dirnhofer, Thilo Zander, Ann-Sofie Johansson, Peter de Nully Brown, Walter Mingrone, Eva Kimby, Bjørn Østenstad, Urban Novak, Daniel Rauch, Björn E. Wahlin, Fatime Krasniqi, Felicitas Hitz, Emanuele Zucca, Michele Ghielmini, Stefanie Hayoz, Hans Hagberg, Hanne Skjerven Bersvendsen, Hanne Hawle, Andrés J.M. Ferreri, Anna Vanazzi, Stephanie Rondeau
Publikováno v:
Blood. 134:353-362
The SAKK 35/10 phase 2 trial, developed by the Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group, compared the activity of rituximab vs rituximab plus lenalidomide in untreated follicular lymphoma patients in need of systemic the
Autor:
Lisa A. Westfield, Ara Metjian, Joshua Muia, Ayad Hamdan, Patricia Nieters, J. Evan Sadler, Anita Rodrigues, Ana G. Antun, Jeffrey I. Zwicker, Leili Dolatshahi
Publikováno v:
Blood
TO THE EDITOR: The introduction of plasmapheresis with plasma exchange has increased survival in patients with thrombotic thrombocytopenic purpura (TTP) from
Autor:
Marion G. Peters, Yasuhito Tanaka, Won Seog Kim, Xiaonan Hong, Kensei Tobinai, Shigeru Kusumoto, Andrew D. Zelenetz, Hiroshi Kuriki, Eisuke Ueda, Jie Jin, Günter Fingerle-Rowson, Hanna Piper-Lepoutre, Luca Arcaini, Tina Nielsen, Yok-Lam Kwong, Gila Sellam
Publikováno v:
Blood. 133:137-146
Risk of hepatitis B virus (HBV) reactivation was assessed in B-cell non-Hodgkin lymphoma (NHL) patients with resolved HBV infection (hepatitis B surface antigen negative, hepatitis B core antibody positive) who received obinutuzumab- or rituximab-con